Area of research
Molecular Biology · Oncology
Research interest
Research interests include Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, Colorectal Cancer Treatments and Studies, and Nonmelanoma Skin Cancer Studies.
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma
A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab
Panniculitis in Patients Treated With BRAF Inhibitors
Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks
Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib
Cutaneous toxicities of RAF inhibitors
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors